Charles River Laboratories CRL Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total Revenue by Business | ||||||
| DSA | $596.92M+0.7% | $591.57M-2.0% | $600.69M-2.3% | $618.03M-1.5% | $592.61M-2.1% | |
| Manufacturing | $190.54M+6.8% | $196.4M+0.7% | $190.69M-3.1% | $200.84M+4.4% | $178.49M-3.6% | |
| RMS | $208.37M-2.2% | $206.26M+1.0% | $213.47M+7.9% | $213.27M+3.3% | $213.07M-3.5% | |
| Total by Business | ||||||
| DSA | $6.88M-60.8% | $13.53M-11.1% | $4.53M-67.3% | $16.08M+327% | $17.54M+170% | |
| Manufacturing | $462K-87.6% | $4.47M+39.0% | $2.64M-50.9% | $7.44M+180% | $3.71M+128% | |
| RMS | $17.63M+1,138% | $4.04M-81.0% | $5.82M+17.3% | $7.42M-27.5% | $1.42M-80.7% | |
| Cost of revenue (excluding amortization of intangible assets) by Business | ||||||
| DSA | $435.16M+3.6% | $435.86M-3.3% | $408.11M-0.4% | $421.91M+0.7% | $420.14M+0.5% | |
| Manufacturing | $112.04M+4.7% | $102.87M-5.6% | $109.94M-2.8% | $110.03M-0.4% | $107M-0.8% | |
| RMS | $153.96M+10.5% | $145.82M-8.1% | $148M+7.3% | $143.14M+0.1% | $139.3M-1.2% | |
| Operating Income (Loss) by Business | ||||||
| DSA | $103.88M+10.6% | $84.67M+34.7% | $123.15M-2.6% | $122.78M-11.3% | $93.95M-18.2% | |
| Manufacturing | $46.84M+643% | -$227.65M-24.7% | $39.93M-0.7% | $12.06M-67.6% | -$8.62M-126% | |
| RMS | $49.77M+14.1% | —— | $34.55M+25.4% | $35.79M+19.5% | $43.61M+1.1% | |
| Segment operating income | $200.49M+55.5% | —— | $197.63M+1.8% | $170.63M-17.0% | $128.94M-32.7% | |
| SG&A by Business | ||||||
| DSA | $47.52M-27.2% | $57.94M-22.2% | $56.27M-11.1% | $60.27M+10.6% | $65.29M+14.8% | |
| Manufacturing | $29.71M-12.7% | $43.1M+29.0% | $32.56M-0.6% | $32.42M-4.1% | $34.03M+3.6% | |
| RMS | $1.6M-93.4% | $24.02M-7.8% | $24.93M-5.7% | $28.37M+2.8% | $24.21M-21.6% | |
| Acquisitions by Business | ||||||
| DSA | $340.99M— | —— | —— | —— | —— | |
| Manufacturing | $0— | —— | —— | —— | —— | |
| RMS | $0— | —— | —— | —— | —— | |
| Goodwill, Gross by Business | ||||||
| DSA | $1.96B— | $1.68B+2.6% | —— | —— | —— | |
| Manufacturing | $570.46M— | $574.89M-19.5% | —— | —— | —— | |
| RMS | $511.1M— | $510.84M+2.8% | —— | —— | —— | |
| Foreign exchange by Business | ||||||
| DSA | -$14.38M-281% | $4.91M+112% | —— | $40.19M+608% | $7.94M+137% | |
| Manufacturing | -$4.43M-144% | $1.53M+107% | —— | $21.92M— | $10.18M+386% | |
| RMS | $257K-98.0% | $539K+158% | $135K-81.7% | $755K+685% | $12.68M+3,214% | |
| Goodwill, Written off Related to Sale of Business Unit by Business | ||||||
| DSA | $46.65M+1,066% | —— | —— | —— | $4M— | |
| Manufacturing | $0— | $0— | $0— | $0— | $0— | |
| RMS | $0— | $0— | $0— | $0— | $0— | |
| Capital Expenditures by Business | ||||||
| DSA | $37.51M+8.7% | $54.23M+45.9% | $25.71M+12.9% | $18.5M-4.9% | $34.52M-29.5% | |
| Manufacturing | $6.27M-63.7% | $7.8M-24.5% | $5.19M-40.6% | $11.16M+5.5% | $17.28M+95.0% | |
| RMS | $11.57M+58.8% | $24.74M-10.3% | $3.17M-55.8% | $3.64M-60.9% | $7.29M-63.6% | |
| D&A by Business | ||||||
| DSA | $39.91M-5.2% | $45.37M-9.0% | $44M-7.9% | $42.58M-10.8% | $42.08M-8.1% | |
| Manufacturing | $8.4M-84.6% | $12.88M-56.8% | $17.38M-14.4% | $55.34M+176% | $54.62M+176% | |
| RMS | $16.14M-25.8% | $17.67M-14.9% | $21.94M+19.3% | $19.71M+19.2% | $21.76M+20.1% | |
| Intangible Amortization by Business | ||||||
| DSA | $10.36M-21.6% | $13.11M-14.8% | $13.15M-16.1% | $13.07M-16.2% | $13.22M-16.5% | |
| Manufacturing | $1.95M-95.8% | $4.1M-79.6% | $8.27M-23.5% | $46.33M+330% | $46.08M+327% | |
| RMS | $3.04M-49.1% | $3.81M-33.6% | $5.98M+1.0% | $5.98M+1.3% | $5.97M+0.4% | |
| Goodwill, impaired, accumulated impairment loss by Business | ||||||
| DSA | $1B0.0% | $1B0.0% | $1B0.0% | $1B0.0% | $1B0.0% | |
| Manufacturing | $380M+76.7% | $380M— | $215M— | $215M— | $215M— | |
| Total Revenue by Geography | ||||||
| Asia Pacific | $55.48M+32.3% | $56.91M+2.0% | $51.66M+14.8% | $54.5M+8.2% | $41.94M-8.4% | |
| Canada | $109.57M-12.6% | $123.28M+3.3% | $116.81M-8.1% | $135.59M+8.3% | $125.35M+13.5% | |
| Europe | $277.58M+5.4% | $279.9M+6.3% | $277.69M+4.0% | $281.86M+3.9% | $263.25M-4.7% | |
| Other | $9.4M-43.6% | $16.79M-2.0% | $21.08M+87.1% | $10.33M+34.4% | $16.67M-0.5% | |
| U.S. | $543.81M+1.3% | $517.35M-5.4% | $537.61M-3.9% | $549.86M-3.8% | $536.96M-4.5% | |
| Long-Lived Assets by Geography | ||||||
| Asia Pacific | $60.91M-5.9% | $61.81M-6.4% | $61.55M-13.1% | $64.18M-6.8% | $64.72M-8.9% | |
| Canada | $162.41M+9.3% | $163.34M+11.1% | $153.67M+0.5% | $156.58M+1.7% | $148.61M-3.1% | |
| Europe | $450.34M+5.4% | $468.64M+13.5% | $446.63M+4.9% | $452M+11.5% | $427.21M+5.6% | |
| Other | $42.48M+11.9% | $42.19M+16.1% | $40.79M+10.8% | $40.11M+13.3% | $37.96M+7.5% | |
| U.S. | $794.02M-12.6% | $919.24M-2.4% | $888.99M-6.8% | $893.87M-5.9% | $908.58M-4.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Charles River Laboratories break its business down?
- Charles River Laboratories (CRL) reports total revenue by business across 3 parts — DSA, Manufacturing and RMS. Each is extracted from the segment footnotes and tracked over time.
- Where does Charles River Laboratories's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Charles River Laboratories's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
